FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2890147972> ?p ?o ?g. }

• W2890147972 abstract "e11072 Background: Lapatinib is an oral dual tyrosin kinase inhibitor of EGFR and HER2 and compared to trastuzumab penetrates to CNS. We evaluated efficacy and safety of lapatinib treatment according to different metastatic sites involvement using data from IntERB registry that has been initiated and run by Czech Society for Oncology and Institute of Biostatistics and Analyses at Masaryk University, Brno, Czech Republic. Methods: An analysis included 213 patients with HER2 positive metastatic breast cancer treated from January 2007 to September 2011. Lapatinib was mostly administered orally 1250mg/day with capecitabine (2000mg/m2 D1-14), 16 patients received lapatinib in monotherapy. All patients had experienced progression during prior trastuzumab based therapy. Results: Median age was 56 years (range 23 – 78). Median duration of lapatinib therapy was 20.6 weeks (range 1–146). Complete response was achieved in 13 patients (6.1%), partial response in 31 (14.6%), stable disease in 118 (55.4%). In 26 disease have progressed (12.2%); response could not be assessed in 25 patients (11.7%). PFS for whole group was 7.1 months (95% CI 5.9-8.5). Overall survival was 17.2m (95% CI 15.8-18.6), probability of 6m OS was 80.3% and 1-year OS was 64%. Metastatic sites specific survival was evaluated in 103 patients. CNS dissemination was initially diagnosed in 31 patients (30.1%), PFS in this group was 6.2m (95% CI 3.3-9.1), OS was not reached, 6-m OS was 67.3%. In non-CNS group (skeletal metastasis in 49.5%, lung 38.8%, hepatic 36.9%, lymphatic 17.5%, other 15.5%) was PFS 6.3m (95% CI 1.6-11.1), OS 22.0m (95% CI 15.3-28.8) and 6-m OS was 88.2%. Most common toxicities were diarrhea in 11.7% patients, rash/skin toxicity in 10.8%, nausea/vomitus in 5.2% and hepatotoxicity in 2.3%. No cardiac toxicity was reported. Therapy was discontinued due toxicity in 9.0%. Conclusions: Lapatinib in combination with capecitabine proved its efficacy in trastuzumab pretreated HER2 positive metastatic breast cancer. Even in patients with CNS involvement was achieved a notable PFS and OS, comparable to non-CNS group of patients. Therapy was well tolerated." @default.
• W2890147972 created "2018-09-27" @default.
• W2890147972 creator A5038719530 @default.
• W2890147972 creator A5039421731 @default.
• W2890147972 creator A5061781467 @default.
• W2890147972 creator A5076974443 @default.
• W2890147972 date "2012-05-20" @default.
• W2890147972 modified "2023-09-27" @default.
• W2890147972 title "Lapatinib efficacy according to metastatic sites in trastuzumab pretreated patients with HER2-positive metastatic breast cancer: An analysis form IntERB registry in the Czech Republic." @default.
• W2890147972 doi "https://doi.org/10.1200/jco.2012.30.15_suppl.e11072" @default.
• W2890147972 hasPublicationYear "2012" @default.
• W2890147972 type Work @default.
• W2890147972 sameAs 2890147972 @default.
• W2890147972 citedByCount "1" @default.
• W2890147972 countsByYear W28901479722020 @default.
• W2890147972 crossrefType "journal-article" @default.
• W2890147972 hasAuthorship W2890147972A5038719530 @default.
• W2890147972 hasAuthorship W2890147972A5039421731 @default.
• W2890147972 hasAuthorship W2890147972A5061781467 @default.
• W2890147972 hasAuthorship W2890147972A5076974443 @default.
• W2890147972 hasConcept C121608353 @default.
• W2890147972 hasConcept C126322002 @default.
• W2890147972 hasConcept C138885662 @default.
• W2890147972 hasConcept C143998085 @default.
• W2890147972 hasConcept C2775930923 @default.
• W2890147972 hasConcept C2777329042 @default.
• W2890147972 hasConcept C2777842544 @default.
• W2890147972 hasConcept C2777909004 @default.
• W2890147972 hasConcept C2779786085 @default.
• W2890147972 hasConcept C2781164504 @default.
• W2890147972 hasConcept C41895202 @default.
• W2890147972 hasConcept C526805850 @default.
• W2890147972 hasConcept C530470458 @default.
• W2890147972 hasConcept C71924100 @default.
• W2890147972 hasConceptScore W2890147972C121608353 @default.
• W2890147972 hasConceptScore W2890147972C126322002 @default.
• W2890147972 hasConceptScore W2890147972C138885662 @default.
• W2890147972 hasConceptScore W2890147972C143998085 @default.
• W2890147972 hasConceptScore W2890147972C2775930923 @default.
• W2890147972 hasConceptScore W2890147972C2777329042 @default.
• W2890147972 hasConceptScore W2890147972C2777842544 @default.
• W2890147972 hasConceptScore W2890147972C2777909004 @default.
• W2890147972 hasConceptScore W2890147972C2779786085 @default.
• W2890147972 hasConceptScore W2890147972C2781164504 @default.
• W2890147972 hasConceptScore W2890147972C41895202 @default.
• W2890147972 hasConceptScore W2890147972C526805850 @default.
• W2890147972 hasConceptScore W2890147972C530470458 @default.
• W2890147972 hasConceptScore W2890147972C71924100 @default.
• W2890147972 hasLocation W28901479721 @default.
• W2890147972 hasOpenAccess W2890147972 @default.
• W2890147972 hasPrimaryLocation W28901479721 @default.
• W2890147972 isParatext "false" @default.
• W2890147972 isRetracted "false" @default.
• W2890147972 magId "2890147972" @default.
• W2890147972 workType "article" @default.